Literature DB >> 22023179

Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia.

Elizabeth Gilday1, Henry A Nasrallah.   

Abstract

Paliperidone Palmitate is a long-acting intramuscular atypical antipsychotic drug indicated for the acute maintenance treatment of schizophrenia in adults. Its mechanism of action, like all other atypical agents, is attributed to the antagonism of brain dopamine D2 and serotonin 5-HT2A receptors. The pharmacodynamics, pharmacokinetics, and metabolism of paliperidone palmitate are reviewed. Current studies for clinical efficacy of paliperidone palmitate for both acute and maintenance treatment and adherence in adults with schizophrenia are discussed. Studies for safety and tolerability are also reviewed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22023179     DOI: 10.2174/157488712799363307

Source DB:  PubMed          Journal:  Rev Recent Clin Trials        ISSN: 1574-8871


  13 in total

Review 1.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

2.  Invega Trinza: The First Four-Times-a-Year, Long-Acting Injectable Antipsychotic Agent.

Authors:  Noor Daghistani; Jose A Rey
Journal:  P T       Date:  2016-04

3.  Summary report of PQRI Workshop on Nanomaterial in Drug Products: current experience and management of potential risks.

Authors:  Jeremy A Bartlett; Marcus Brewster; Paul Brown; Donna Cabral-Lilly; Celia N Cruz; Raymond David; W Mark Eickhoff; Sabine Haubenreisser; Abigail Jacobs; Frank Malinoski; Elaine Morefield; Ritu Nalubola; Robert K Prud'homme; Nakissa Sadrieh; Christie M Sayes; Hripsime Shahbazian; Nanda Subbarao; Lawrence Tamarkin; Katherine Tyner; Rajendra Uppoor; Margaret Whittaker-Caulk; William Zamboni
Journal:  AAPS J       Date:  2014-11-25       Impact factor: 4.009

4.  Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.

Authors:  Natalie J Carter
Journal:  Drugs       Date:  2012-05-28       Impact factor: 9.546

5.  Effects of paliperidone palmitate on coagulation: an experimental study.

Authors:  Enver Demirel Yılmaz; Sedat Motor; Fatih Sefil; Neslihan Pınar; Hanifi Kokacya; Mustafa Kisa; Suleyman Oktar
Journal:  ScientificWorldJournal       Date:  2014-02-09

6.  Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia.

Authors:  Fan Zhang; Tianmei Si; Chiun-Fang Chiou; Anthony Wf Harris; Chang Yoon Kim; Padmashree Jahagirdar; Steve Ascher
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-11       Impact factor: 2.570

Review 7.  A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder.

Authors:  Pierre Chue; James Chue
Journal:  Ther Clin Risk Manag       Date:  2016-01-27       Impact factor: 2.423

8.  The cost reduction in hospitalization associated with paliperidone palmitate in the People's Republic of China, Korea, and Malaysia.

Authors:  Chiun-Fang Chiou; Bruce Cm Wang; Ronald Caldwell; Wesley Furnback; Jung-Sun Lee; Nathan Kothandaraman; SunKyoung Lee; Jin Wang; Fan Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2015-08-05       Impact factor: 2.570

Review 9.  Clinical pharmacology of atypical antipsychotics: an update.

Authors:  M C Mauri; S Paletta; M Maffini; A Colasanti; F Dragogna; C Di Pace; A C Altamura
Journal:  EXCLI J       Date:  2014-10-13       Impact factor: 4.068

Review 10.  Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia.

Authors:  Claudio Brasso; Silvio Bellino; Paola Bozzatello; Cristiana Montemagni; Paola Rocca
Journal:  Neuropsychiatr Dis Treat       Date:  2017-11-07       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.